Open an account

Perspective Therapeutics

CATX · NYSE American

$2.30+$0.11 (+5.02%)TodayMarket closed ·
Prev close $2.19

About CATX

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company is headquartered in Seattle, Washington and currently employs 163 full-time employees. The company went IPO on 2002-05-31. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Employees
163
Headquarters
Seattle, Washington
Listed
May 31, 2002
Sector
Health Care
Industry
Biotechnology
Website
perspectivetherapeutics.com

CATX key statistics

Market cap
262.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.03M
Volume
1.81M
Open price
$2.19
High today
$2.37
Low today
$2.19
52 Week high
$6.16
52 Week low
$1.96

Perspective Therapeutics (CATX) at a glance

As of Oct 20, 2026, Perspective Therapeutics (CATX) shares are priced at $2.30, giving the company a market cap of 262.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.19 and $2.37. The current price is 5.0% above the day's low and 3.0% below its high.

Volume so far is 1.81M shares, in line with the average of 2.03M shares a day.

Over the past year Perspective Therapeutics has ranged from $1.96 to $6.16, and now sits 8% of the way up that range.

Perspective Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.22 per share against an estimate of -$0.2615.

The average analyst price target is $12.53, 444.8% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

91%of 11 analyst ratings say Buy
  • Buy90.9%
  • Hold9.1%
  • Sell0.0%
Price target · 16 analystsAvg $12.53
Low
$5.05
Now
$2.30
High
$18.90

CATX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 11.8% on average.

  1. Q3 FY24: reported -$0.21 per share against an estimate of -$0.2176
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.2717
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.3134
  4. Q2 FY25: reported -$0.29 per share against an estimate of -$0.3079
  5. Q3 FY25: reported -$0.35 per share against an estimate of -$0.3328
  6. Q4 FY25: reported -$0.51 per share against an estimate of -$0.3636
  7. Q1 FY26: reported -$0.25 per share against an estimate of -$0.3021
  8. Q2 FY26: reported -$0.22 per share against an estimate of -$0.2615

CATX news

  • Press releaseGlobe Newswire

    Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

  • Press releaseGlobe Newswire

    Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium

  • Press releaseGlobe Newswire

    Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

  • Vandana Singh

    This $3 Biotech Could Be Worth $11.45, Analyst Says

  • Press releaseGlobe Newswire

    Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

  • Press releaseGlobe Newswire

    Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026

  • Press releaseGlobe Newswire

    Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

  • Press releaseGlobe Newswire

    Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Perspective Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.